{"id":"placebo-group-vehicle","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo groups in clinical trials receive a formulation identical in appearance and administration to the active drug but lacking the therapeutic agent. This allows researchers to isolate the true pharmacological effect of the investigational drug by controlling for placebo response, natural disease progression, and observer bias. Placebo controls are the gold standard for establishing drug efficacy in Phase 3 trials.","oneSentence":"A placebo (vehicle control) contains no active pharmaceutical ingredient and serves as an inert comparator in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:36.195Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06146634","phase":"NA","title":"Washington State Driving Intervention Research Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2024-07-15","conditions":"Driving Behavior","enrollment":8000},{"nctId":"NCT07469228","phase":"PHASE1","title":"A Study Comparing Tretinoin Gel Microsphere, 0.04% and RETIN-A MICRO ® Gel Microsphere, 0.04% in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2025-08-04","conditions":"Acne Vulgaris","enrollment":1043},{"nctId":"NCT03961347","phase":"PHASE2","title":"Lactobacillus Johnsonii Supplementation in Adults With T1D","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2020-02-01","conditions":"Type 1 Diabetes (T1D)","enrollment":46},{"nctId":"NCT03961854","phase":"PHASE2","title":"Lactobacillus Johnsonii in Children and Adolescents With T1D","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-10-10","conditions":"Type 1 Diabetes (T1D)","enrollment":30},{"nctId":"NCT07369869","phase":"NA","title":"Evaluating the Effects of Nutritional Interventions on Sleep, the Gut Microbiome, Cognition, and Stress.","status":"NOT_YET_RECRUITING","sponsor":"Northumbria University","startDate":"2026-05","conditions":"Stress, Sleep, Cognition","enrollment":68},{"nctId":"NCT05171894","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT","status":"RECRUITING","sponsor":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","startDate":"2024-09-21","conditions":"Port-wine Birthmarks, Port-Wine Stain, Nevus Flammeus","enrollment":84},{"nctId":"NCT05005845","phase":"PHASE2","title":"NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)","status":"COMPLETED","sponsor":"NFlection Therapeutics, Inc.","startDate":"2021-09-29","conditions":"Cutaneous Neurofibroma, Neurofibromatosis 1","enrollment":199},{"nctId":"NCT06244316","phase":"PHASE2","title":"A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2024-01-22","conditions":"Dry Eye Disease","enrollment":317},{"nctId":"NCT07264517","phase":"PHASE2","title":"Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).","status":"RECRUITING","sponsor":"Instituto Grifols, S.A.","startDate":"2025-11-03","conditions":"Dry Eye Disease","enrollment":100},{"nctId":"NCT03972592","phase":"PHASE2","title":"Topical Sirolimus in Cutaneous Lymphatic Malformations","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2019-06-05","conditions":"Vascular Malformations, Lymphatic Malformation","enrollment":55},{"nctId":"NCT02633163","phase":"PHASE2","title":"Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2018-11-18","conditions":"Systemic Lupus Erythematosus","enrollment":81},{"nctId":"NCT03483246","phase":"PHASE3","title":"Impact of Fecal Microbiota Transplantation in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-09-17","conditions":"Ulcerative Colitis","enrollment":150},{"nctId":"NCT06742957","phase":"PHASE3","title":"Study Comparing Tapinarof Cream 1% To VTAMA ® (Tapinarof Cream 1%) In the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2024-12-17","conditions":"Plaque Type Psorisis","enrollment":560},{"nctId":"NCT07245017","phase":"EARLY_PHASE1","title":"JN002 for the Treatment of Dry Eye Disease","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-11-24","conditions":"Dry Eye","enrollment":30},{"nctId":"NCT07254663","phase":"","title":"GEL & MEDication Dysphagia","status":"RECRUITING","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2025-09-15","conditions":"Neurological Diseases or Conditions, Healthy Participants","enrollment":500},{"nctId":"NCT04735393","phase":"PHASE3","title":"A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Clinical Trial Evaluating the Safety of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease","status":"COMPLETED","sponsor":"Aldeyra Therapeutics, Inc.","startDate":"2021-01-26","conditions":"Dry Eye Disease","enrollment":757},{"nctId":"NCT05802173","phase":"PHASE2","title":"Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia","status":"COMPLETED","sponsor":"Technoderma Medicines Inc.","startDate":"2023-03-06","conditions":"Alopecia, Androgenetic","enrollment":71},{"nctId":"NCT02427464","phase":"PHASE3","title":"Phase 3 Gene Therapy for Painful Diabetic Neuropathy","status":"COMPLETED","sponsor":"Helixmith Co., Ltd.","startDate":"2016-04","conditions":"Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful","enrollment":507},{"nctId":"NCT03404024","phase":"PHASE2","title":"Safety and Efficacy Study of Gene Therapy for Acute Myocardial Infarction in Korea","status":"WITHDRAWN","sponsor":"Helixmith Co., Ltd.","startDate":"2018-01-25","conditions":"Ischemic Heart Disease, Acute Myocardial Infarction","enrollment":""},{"nctId":"NCT07026318","phase":"NA","title":"Endovascular Therapy Combined With Tirofiban for Intracranial Atherosclerotic Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2025-08-15","conditions":"Acute Ischemic Stroke","enrollment":716},{"nctId":"NCT04874012","phase":"PHASE2","title":"Taurine Effect on Glycemic, Lipidic and Inflammatory Profile in Individuals With Type 2 Diabetes","status":"RECRUITING","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2021-06-12","conditions":"Diabetes Mellitus, Type 2","enrollment":94},{"nctId":"NCT06493578","phase":"PHASE2","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vyne Therapeutics Inc.","startDate":"2024-06-04","conditions":"Non-segmental Vitiligo","enrollment":200},{"nctId":"NCT06802380","phase":"PHASE1, PHASE2","title":"Neuromodulation in Patients With Pulmonary Arterial Hypertension","status":"NOT_YET_RECRUITING","sponsor":"University of Oklahoma","startDate":"2025-09-01","conditions":"Pulmonary Hypertension","enrollment":50},{"nctId":"NCT06880276","phase":"PHASE3","title":"Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-05-16","conditions":"Atopic Dermatitis","enrollment":360},{"nctId":"NCT07131150","phase":"PHASE2","title":"Menstrual Blood-Derived Mesenchymal Stem Cell Injection (SC01009) in the Treatment of Idiopathic Pulmonary Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-08-31","conditions":"Idiopathic Pulmonary Fibrosis (IPF)","enrollment":66},{"nctId":"NCT07120308","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects Caused by Neurotrophic Keratitis","status":"COMPLETED","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2021-09-15","conditions":"Corneal Epithelial Defect","enrollment":28},{"nctId":"NCT06209320","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Two Low-concentration Atropine Sulfate Eye Drops","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.","startDate":"2022-03-15","conditions":"Myopia","enrollment":777},{"nctId":"NCT05376176","phase":"PHASE2","title":"A Multicenter Study Assessing the Efficacy and Safety of STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2022-05-19","conditions":"Fuchs Endothelial Corneal Dystrophy","enrollment":86},{"nctId":"NCT06531512","phase":"PHASE2, PHASE3","title":"Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers","status":"RECRUITING","sponsor":"Oneness Biotech Co., Ltd.","startDate":"2024-08-16","conditions":"Diabetic Foot Ulcer","enrollment":120},{"nctId":"NCT04462536","phase":"PHASE3","title":"Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis","status":"COMPLETED","sponsor":"NoNO Inc.","startDate":"2020-12-06","conditions":"Stroke, Acute","enrollment":850},{"nctId":"NCT05035342","phase":"PHASE3","title":"Fecal Transplantation to Eradicate Colonizing Emergent Superbugs","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-01-11","conditions":"Enterobacteriaceae Infections, Fecal Microbiota Transplantation","enrollment":214},{"nctId":"NCT05297760","phase":"PHASE1, PHASE2","title":"Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2022-02-10","conditions":"Rhinitis, Allergic, Seasonal, Rhinitis; Allergic, With Asthma, Allergic Rhinitis","enrollment":60},{"nctId":"NCT06903611","phase":"PHASE3","title":"Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye","status":"NOT_YET_RECRUITING","sponsor":"Cambium Bio Limited","startDate":"2025-09-30","conditions":"Dry Eye Disease, Dry Eye, Dry Eyes Chronic","enrollment":400},{"nctId":"NCT06891040","phase":"PHASE2","title":"Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis","status":"RECRUITING","sponsor":"Jiangsu vcare pharmaceutical technology co., LTD","startDate":"2025-04-28","conditions":"Atopic Dermatitis","enrollment":114},{"nctId":"NCT05799157","phase":"PHASE2","title":"Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts","status":"COMPLETED","sponsor":"Veradermics, Inc.","startDate":"2023-02-28","conditions":"Verruca Vulgaris, Warts, Common Wart","enrollment":153},{"nctId":"NCT04313400","phase":"PHASE1, PHASE2","title":"Topically Applied AMTX-100 CF for Adult Patients With Mild to Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Amytrx Therapeutics, Inc.","startDate":"2020-03-10","conditions":"Atopic Dermatitis","enrollment":91},{"nctId":"NCT06812637","phase":"PHASE1","title":"Efficacy and Safety of Wharton's Jelly-Derived Mesenchymal Stem Cell Exosomes in the Treatment of Diabetic Foot Ulcers: A Double-blinded Randomized Controlled Clinical Trial","status":"COMPLETED","sponsor":"Kafrelsheikh University","startDate":"2024-04-06","conditions":"Diabetic Foot Ulcer (DFU), Exosomes","enrollment":110},{"nctId":"NCT06363461","phase":"PHASE2","title":"Study of TDM-180935 in Atopic Dermatitis Patients","status":"COMPLETED","sponsor":"Technoderma Medicines Inc.","startDate":"2024-04-13","conditions":"Atopic Dermatitis","enrollment":24},{"nctId":"NCT06129136","phase":"NA","title":"The Effect of Nature-based Exposure on the Immune System and Skin Health of Atopic Dermatitis Patients.","status":"COMPLETED","sponsor":"Uute Scientific Oy","startDate":"2023-08-17","conditions":"Atopic Dermatitis","enrollment":142},{"nctId":"NCT04962139","phase":"PHASE3","title":"Evaluate the Safety and Efficacy of ON101 Cream for the Treatment of Chronic Diabetic Foot Ulcers","status":"TERMINATED","sponsor":"Oneness Biotech Co., Ltd.","startDate":"2021-07-27","conditions":"Chronic Diabetic Foot Ulcers","enrollment":12},{"nctId":"NCT06058000","phase":"PHASE2","title":"A Phase 2 Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2023-11-13","conditions":"Atopic Dermatitis","enrollment":120},{"nctId":"NCT01449513","phase":"PHASE1","title":"PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2011-09","conditions":"Actinic Keratosis","enrollment":24},{"nctId":"NCT02808676","phase":"NA","title":"SYNchronizing Exercises, Remedies in GaIt and Cognition","status":"TERMINATED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2016-07-14","conditions":"Mild Cognitive Impairment","enrollment":175},{"nctId":"NCT04097730","phase":"PHASE3","title":"Steroids and Cross-linking for Ulcer Treatment","status":"COMPLETED","sponsor":"Thomas M. Lietman","startDate":"2020-09-24","conditions":"Keratitis Bacterial","enrollment":280},{"nctId":"NCT05403827","phase":"PHASE3","title":"A Study to Confirm the Efficacy and Safety of K-161 Ophthalmic Solution for Treatment of Moderate to Severe Dry Eye Disease","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2022-07-03","conditions":"Dry Eye Disease","enrollment":644},{"nctId":"NCT06361238","phase":"PHASE3","title":"Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-11-19","conditions":"Delirium, Postoperative","enrollment":260},{"nctId":"NCT06733402","phase":"PHASE1","title":"A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2024-06-20","conditions":"Acne Vulgaris","enrollment":1000},{"nctId":"NCT03812874","phase":"PHASE1, PHASE2","title":"A Study of PTX-9908 Injection for Non-resectable HCC with TACE","status":"RECRUITING","sponsor":"TCM Biotech International Corp.","startDate":"2020-10-06","conditions":"Carcinoma, Hepatocellular","enrollment":50},{"nctId":"NCT06678399","phase":"PHASE1, PHASE2","title":"Phase 1B/2 Clinical Trial Assessing the Safety, Tolerability and Preliminary Efficacy of the Intravenous Administration of Allogeneic Placental Mesenchymal Cells for the Preemptive Treatment of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery","status":"NOT_YET_RECRUITING","sponsor":"Kelifarma","startDate":"2025-04-01","conditions":"Preemptive Therapy of Patients At Risk for Acute Kidney Injury Following Cardiac Surgery","enrollment":91},{"nctId":"NCT06673654","phase":"PHASE1","title":"A Study, Comparing Ruxolitinib Topical Cream 1.5% (Taro Pharmaceuticals U.S.A, Inc.) to OPZELURA (Ruxolitinib) Cream for the Treatment of Mild-to-Moderate Atopic Dermatitis.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2023-08-11","conditions":"Atopic Dermatitis","enrollment":476},{"nctId":"NCT06673641","phase":"PHASE1","title":"A Study Comparing Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Topical Gel 0.15%;3.1%;1.2% (Taro Pharmaceuticals U.S.A., Inc.) and CABTREO Topical Gel for the Treatment of Acne Vulgaris.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2024-05-13","conditions":"Acne Vulgaris","enrollment":382},{"nctId":"NCT04250207","phase":"PHASE2","title":"Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2020-06-23","conditions":"Fuchs' Endothelial Corneal Dystrophy","enrollment":65},{"nctId":"NCT06145035","phase":"PHASE2","title":"Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy","status":"RECRUITING","sponsor":"Roberto Bolli","startDate":"2024-03-04","conditions":"Ischemic Heart Disease","enrollment":60},{"nctId":"NCT06617247","phase":"EARLY_PHASE1","title":"Effects of Cannabidiol on Burnout Syndrome and Empathy of Caregivers of Older Adults","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo","startDate":"2024-12-01","conditions":"Burnout Syndrome","enrollment":26},{"nctId":"NCT05550337","phase":"PHASE3","title":"Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2022-09-19","conditions":"Acne Vulgaris","enrollment":807},{"nctId":"NCT06603857","phase":"PHASE2, PHASE3","title":"Skin Care Regimen for Improving Photoaging Signs on the Face","status":"NOT_YET_RECRUITING","sponsor":"Goldman, Butterwick, Fitzpatrick and Groff","startDate":"2024-09-27","conditions":"Improve Photoaging Signs","enrollment":40},{"nctId":"NCT05712460","phase":"PHASE1","title":"A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-02-08","conditions":"Respiratory Syncytial Viruses","enrollment":12},{"nctId":"NCT05888922","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia","status":"NOT_YET_RECRUITING","sponsor":"Industrial Farmacéutica Cantabria, S.A.","startDate":"2024-09","conditions":"Androgenetic Alopecia, Female Pattern Baldness","enrollment":520},{"nctId":"NCT05763082","phase":"PHASE3","title":"Bioequivalence Study of Two Treatments for the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Padagis LLC","startDate":"2023-02-07","conditions":"Plaque Psoriasis","enrollment":414},{"nctId":"NCT04792580","phase":"EARLY_PHASE1","title":"The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease","status":"COMPLETED","sponsor":"Richard W Yee, MD","startDate":"2022-10-22","conditions":"Graft-versus-host-disease, Ocular Graft-versus-host Disease","enrollment":30},{"nctId":"NCT04811131","phase":"PHASE2","title":"Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo","status":"TERMINATED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2021-03-04","conditions":"Vitiligo","enrollment":114},{"nctId":"NCT05665387","phase":"PHASE2","title":"Study Assessing the Efficacy and Safety of STN1013600 Ophthalmic Solution 0.1% and 0.3% Compared With Placebo in Subjects With Presbyopia","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2022-12-22","conditions":"Presbyopia","enrollment":79},{"nctId":"NCT06403748","phase":"NA","title":"Effect of a Dietary Supplement on Lipid Pattern, Indexes of NAFLD and Systemic Inflammation in Healthy Subjects With Suboptimal LDL-C Levels","status":"NOT_YET_RECRUITING","sponsor":"University of Bologna","startDate":"2024-05-06","conditions":"Hypercholesterolemia, Inflammation","enrollment":90},{"nctId":"NCT06337981","phase":"PHASE2","title":"Efficacy and Safety of AJU-S56 in Dry Eye Syndrome Patients","status":"COMPLETED","sponsor":"AJU Pharm Co., Ltd.","startDate":"2021-11-22","conditions":"Dry Eye Syndromes","enrollment":99},{"nctId":"NCT01744704","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability and Pharmacokinetics of rhNGF Eye Drops in Healthy Volunteers","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2012-07","conditions":"Healthy","enrollment":74},{"nctId":"NCT05231044","phase":"PHASE3","title":"A Multi-Center Study to Evaluate the Efficacy and Safety of KX01 Ointment 1% on Actinic Keratosis on Face or Scalp","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2021-12-21","conditions":"Actinic Keratosis","enrollment":108},{"nctId":"NCT03982368","phase":"PHASE2","title":"A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2019-06-10","conditions":"Dry Eye Syndrome","enrollment":261},{"nctId":"NCT01756456","phase":"PHASE1, PHASE2","title":"Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2013-01","conditions":"Neurotrophic Keratitis, Keratitis, Corneal Ulcer","enrollment":174},{"nctId":"NCT02110225","phase":"PHASE1, PHASE2","title":"A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2014-01","conditions":"Retinitis Pigmentosa","enrollment":50},{"nctId":"NCT03094403","phase":"PHASE1","title":"To Evaluate the Therapeutic Equivalence and Safety of Azelaic Acid 15% Topical Gel","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2016-07-01","conditions":"Rosacea","enrollment":1000},{"nctId":"NCT06291194","phase":"PHASE3","title":"Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients","status":"RECRUITING","sponsor":"AJU Pharm Co., Ltd.","startDate":"2023-11-10","conditions":"Dry Eye Syndromes","enrollment":396},{"nctId":"NCT04378569","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2020-04-20","conditions":"Chronic Hand Eczema","enrollment":230},{"nctId":"NCT04435392","phase":"PHASE1, PHASE2","title":"Jaktinib Hydrochloride Cream For Atopic Dermatitis","status":"COMPLETED","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2020-10-14","conditions":"Atopic Dermatitis","enrollment":107},{"nctId":"NCT06305637","phase":"PHASE1","title":"A Study Comparing Ketoconazole Shampoo, 2% and Ketoconazole 2% Shampoo (RS) in the Treatment of Tinea Versicolor.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2023-12-04","conditions":"Tinea Versicolor","enrollment":430},{"nctId":"NCT06231771","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Stem Cells for Diabetic Foot Ulcer","status":"NOT_YET_RECRUITING","sponsor":"Supergenics Life Science Sdn. Bhd.","startDate":"2024-05","conditions":"Diabetic Foot Ulcer","enrollment":22},{"nctId":"NCT04289194","phase":"PHASE1, PHASE2","title":"Clinical Study to Assess the Safety and Preliminary Efficacy of HCR040 in Acute Respiratory Distress Syndrome","status":"COMPLETED","sponsor":"Histocell, S.L.","startDate":"2019-12-10","conditions":"Acute Respiratory Distress Syndrome","enrollment":26},{"nctId":"NCT03442751","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus","status":"COMPLETED","sponsor":"Glaukos Corporation","startDate":"2018-04-06","conditions":"Progressive Keratoconus","enrollment":201},{"nctId":"NCT06106880","phase":"PHASE1","title":"Alleviation of Common Cold Symptoms","status":"COMPLETED","sponsor":"Applied Biological Laboratories Inc","startDate":"2022-05-25","conditions":"Common Cold, Pharyngitis, Fever","enrollment":157},{"nctId":"NCT06200883","phase":"PHASE4","title":"Effects of a Nutraceutic Compound on Cognitive Impairment","status":"COMPLETED","sponsor":"Federico II University","startDate":"2022-09-01","conditions":"Mild Cognitive Impairment","enrollment":58},{"nctId":"NCT03836859","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2018-03-30","conditions":"Healthy Volunteers","enrollment":30},{"nctId":"NCT02342691","phase":"PHASE1, PHASE2","title":"Safety and Preliminary Efficacy of Lipoxin Analog BLXA4-ME Oral Rinse for the Treatment of Gingivitis","status":"COMPLETED","sponsor":"The Forsyth Institute","startDate":"2015-04","conditions":"Gingival Inflammation","enrollment":127},{"nctId":"NCT04778059","phase":"PHASE2","title":"Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19","status":"TERMINATED","sponsor":"US Biotest, Inc.","startDate":"2021-07-27","conditions":"2019 Novel Coronavirus Infection, COVID-19 Virus Infection, SARS Coronavirus 2 Infection","enrollment":21},{"nctId":"NCT05796609","phase":"NA","title":"Design and Evaluation of an In-Vehicle Real-Time Drunk Driving Detection System","status":"COMPLETED","sponsor":"University of Bern","startDate":"2023-04-05","conditions":"Drunk Driving, Alcohol Drinking, Impaired Driving","enrollment":55},{"nctId":"NCT06151587","phase":"PHASE3","title":"A Phase 3 Clinical Study of QLM3004 in Delaying Myopia in Children","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2023-08-20","conditions":"Myopia","enrollment":735},{"nctId":"NCT04037475","phase":"NA","title":"Treatment of Herpes Labialis by Photodynamic Therapy","status":"COMPLETED","sponsor":"University of Nove de Julho","startDate":"2020-01-01","conditions":"Photodynamic Therapy, Herpes Simplex, Labial","enrollment":24},{"nctId":"NCT05525468","phase":"PHASE1","title":"A Phase 1 Study of TDM-180935 Following Topical Administration in Healthy Male Subjects","status":"COMPLETED","sponsor":"Technoderma Medicines Inc.","startDate":"2023-02-08","conditions":"Healthy","enrollment":58},{"nctId":"NCT04020419","phase":"EARLY_PHASE1","title":"Natural Berry Extract Treatment of Hemangiomas","status":"TERMINATED","sponsor":"Gayle Gordillo","startDate":"2020-12-01","conditions":"Hemangioma","enrollment":12},{"nctId":"NCT04037709","phase":"NA","title":"Photodynamic Therapy in Patients With Gingivitis","status":"COMPLETED","sponsor":"University of Nove de Julho","startDate":"2020-11-09","conditions":"Gingivitis, Orthodontic Appliance Complication, Photodynamic Therapy","enrollment":20},{"nctId":"NCT06063473","phase":"PHASE1","title":"A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2023-02-22","conditions":"Acne Vulgaris","enrollment":762},{"nctId":"NCT05400031","phase":"NA","title":"Oral Care With Propolis in Pediatric Oncology Patients","status":"COMPLETED","sponsor":"Izmir Katip Celebi University","startDate":"2022-06-01","conditions":"Oral Mucositis","enrollment":108},{"nctId":"NCT04867434","phase":"PHASE2","title":"Efficacy and Safety of RZL-012 on Submental Fat Reduction","status":"COMPLETED","sponsor":"Raziel Therapeutics Ltd.","startDate":"2021-06-15","conditions":"Submental Fat","enrollment":151},{"nctId":"NCT03370874","phase":"PHASE3","title":"Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers.","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2018-06-27","conditions":"Diabetic Foot Ulcer","enrollment":150},{"nctId":"NCT05995392","phase":"EARLY_PHASE1","title":"The Effects and Safety of Topical Spironolactone Ophthalmic Solution, 0.005 mg/cc in Subjects With Dry Eye Disease","status":"UNKNOWN","sponsor":"Richard W Yee, MD","startDate":"2023-08","conditions":"Dry Eye Disease","enrollment":30},{"nctId":"NCT04770610","phase":"PHASE3","title":"Study of OT-101 in Treating Myopia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ocumension (Hong Kong) Limited","startDate":"2021-04-01","conditions":"Myopia, Progressive","enrollment":678},{"nctId":"NCT04810962","phase":"PHASE3","title":"Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study","status":"COMPLETED","sponsor":"Formosa Pharmaceuticals, Inc.","startDate":"2021-03-16","conditions":"Ocular Inflammation and Pain After Cataract Surgery","enrollment":370},{"nctId":"NCT02667444","phase":"PHASE3","title":"P3 Study Comparing Once Daily SB204 and Vehicle Gel in Acne","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2016-02-19","conditions":"Acne Vulgaris","enrollment":1330},{"nctId":"NCT02672332","phase":"PHASE3","title":"P3 Study in Acne Comparing Once Daily SB204 and Vehicle","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2016-02-22","conditions":"Acne Vulgaris","enrollment":1307},{"nctId":"NCT04739709","phase":"PHASE3","title":"Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery","status":"COMPLETED","sponsor":"Formosa Pharmaceuticals, Inc.","startDate":"2021-01-11","conditions":"Ocular Inflammation and Pain","enrollment":378},{"nctId":"NCT04091646","phase":"PHASE2","title":"Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis","status":"COMPLETED","sponsor":"Arcutis Biotherapeutics, Inc.","startDate":"2019-12-04","conditions":"Seborrheic Dermatitis","enrollment":226},{"nctId":"NCT04684121","phase":"PHASE2","title":"Study of the Efficacy and Safety of Granexin® Gel to Improve Burn Wound Healing","status":"WITHDRAWN","sponsor":"Xequel Bio, Inc.","startDate":"2022-08-01","conditions":"Second Degree Burn, Thermal Burn","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Control Group"],"phase":"phase_3","status":"active","brandName":"Placebo Group(Vehicle)","genericName":"Placebo Group(Vehicle)","companyName":"AJU Pharm Co., Ltd.","companyId":"aju-pharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}